Position in GRFS
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$152,428
+$25,549 QoQ
Shares Held
19,006
+40.1% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 53.814584867936446.ToString("F0")%
Shared 18.420498789855834.ToString("F0")%
None 27.764916342207723.ToString("F0")%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Savant Capital, LLC holds $182,516,970 across 15 Drug Manufacturers - General names. GRFS ranks #15 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
223,783 | $54,701,516 | |
| 2 | LLY |
ELI LILLY & Co
|
52,081 | $47,902,541 | |
| 3 | ABBV |
AbbVie Inc.
|
163,461 | $35,551,132 | |
| 4 | MRK |
Merck & Co., Inc.
|
106,935 | $12,863,211 | |
| 5 | AMGN |
Amgen Inc
|
25,466 | $8,960,212 | |
| 6 | PFE |
Pfizer Inc
|
194,065 | $5,449,345 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
77,258 | $4,685,697 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
30,192 | $4,207,859 |
All Filings in GRFS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $152,428 | 19,006 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $126,879 | 13,570 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $126,681 | 12,719 | Shares | Sole | 2026-03-04 | |
| 2025-06-30 | $101,121 | 11,186 | Shares | Sole | 2026-03-04 | |
| 2025-03-31 | $83,229 | 11,706 | Shares | Sole | 2026-03-04 | |
| No filing history on record for this holder in this stock. | ||||||